CDK12 INHIBITION REVERSES DE NOVO AND ACQUIRED PARP INHIBITOR RESISTANCE IN BRCA WILD-TYPE AND MUTATED MODELS OF TRIPLE-NEGATIVE BREAST CANCER

Although poly (ADP-ribose) polymerase (PARP) inhibitors are active in homologous recombination (HR)-deficient cancers, their utility is limited by acquired resistance following restoration of HR. Here, we report that dinaciclib, an inhibitor of cyclin-dependent kinases (CDKs) 1, 2, 5 and 9, addition...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cell Rep
Main Authors: Johnson, Shawn F., Cruz, Cristina, Greifenberg, Ann Katrin, Dust, Sofia, Stover, Daniel G., Chi, David, Primack, Benjamin, Cao, Shiliang, Bernhardy, Andrea J., Coulson, Rhiannon, Lazaro, Jean-Bernard, Kachupurakkal, Bose, Sun, Heather, Unitt, Christine, Moreau, Lisa A., Sarosiek, Kristopher A., Scaltriti, Maurizio, Juric, Dejan, Baselga, José, Richardson, Andrea L., Rodig, Scott J., D’Andrea, Alan D., Balmaña, Judith, Johnson, Neil, Geyer, Matthias, Serra, Violeta, Lim, Elgene, Shapiro, Geoffrey I.
格式: Artigo
語言:Inglês
出版: 2016
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5176643/
https://ncbi.nlm.nih.gov/pubmed/27880910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2016.10.077
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍